i-SENS, Inc.
Financials
Valuation Metrics
i-SENS, Inc.'s Market Cap is ₩5205B. At end of 2025 it was ₩4572B. Ranked #442 of 2,436 in KR market (top 18%), #156 of 1,649 on KOSDAQ (top 9%), #11 of 96 in Health Care Equipment & Services (top 11%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 520.51B KRW | KR#442/2,436 Sec#11/96 |
| Revenue | 314.31B KRW | KR#803/2,436 Sec#8/96 |
| Net Income | -7.30B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 591.04B KRW | KR#665/2,436 Sec#9/96 |
| Net Assets | 356.49B KRW | KR#632/2,436 Sec#9/96 |
| Employees | 904 | KR#279/2,436 Sec#2/96 |
| Value | ||
| P/B | 1.46x | KR#1,769/2,436 Sec#57/96 |
| P/S | 1.66x | KR#1,724/2,436 Sec#43/96 |
| EV/EBITDA | 114.51x | KR#1,484/2,436 Sec#47/96 |
| FCF Yield | -1.46% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -2.05% | KR#1,618/2,436 Sec#54/96 |
| ROA | -1.24% | KR#1,624/2,436 Sec#52/96 |
| Op. Margin | 1.78% | KR#1,384/2,436 Sec#49/96 |
| Revenue Growth | -1.49% | KR#1,526/2,436 Sec#67/96 |
| Earnings Growth | -27.56% | KR#1,093/2,436 Sec#41/96 |
| Financial Health | ||
| Debt Ratio | 65.80% | KR#222/2,436 Sec#9/96 |
| Total Debt | 167.74B KRW | KR#544/2,436 Sec#7/96 |
| FCF | -7.60B KRW | KR#1,623/2,436 Sec#59/96 |
| Cash | 48.25B KRW | KR#771/2,436 Sec#11/96 |
| Current Ratio | 1.70x | KR#1,146/2,436 Sec#62/96 |
| Net Debt/EBITDA | 21.38x | KR#1,434/2,436 Sec#49/96 |
| Dividend | ||
| Div. Yield | 0.60% | KR#1,258/2,436 Sec#39/96 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | 1.06% | KR#693/2,436 Sec#17/96 |
| 1M Return | 13.20% | KR#206/2,436 Sec#13/96 |
| From 52W High | -34.42% | KR#546/2,436 Sec#19/96 |
| 1Y MDD | -45.59% | KR#727/2,436 Sec#22/96 |
| Trading | ||
| Volume | 100,198 shares | KR#941/2,436 Sec#37/96 |
| Foreign Own. | 25.93% | KR#154/2,436 Sec#4/96 |
| Per Share | ||
| EPS | -209 KRW | KR—/2,436 Sec—/96 |
| BPS | 11,625 KRW | KR#843/2,436 Sec#15/96 |
Company Info
Established in 2000, this company develops, manufactures, and sells medical sensors and measuring instruments using electrochemical and biosensor technologies. Its blood glucose meter segment, including self-monitoring and continuous glucose monitoring systems, accounts for over 80% of sales, while the point-of-care testing (POCT) segment for critical care analysis equipment contributes 10%. The company holds world-leading technology for blood sample volume (0.5㎕) and measurement speed (5 seconds), expanding global market share with the domestic launch of CareSens Air, the first continuous glucose monitoring system in Korea. i-SENS is headquartered in Seocho-gu, Seoul.